These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 31028836)

  • 21. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
    Leal AD; Krishnamurthy A; Head L; Messersmith WA
    Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Fluorophore-Labeled Thailanstatin Antibody-Drug Conjugates for Cellular Trafficking Studies.
    Kulkarni C; Finley JE; Bessire AJ; Zhong X; Musto S; Graziani EI
    Bioconjug Chem; 2017 Apr; 28(4):1041-1047. PubMed ID: 28191936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
    Birrer MJ; Moore KN; Betella I; Bates RC
    J Natl Cancer Inst; 2019 Jun; 111(6):538-549. PubMed ID: 30859213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
    Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
    Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates.
    Khera E; Thurber GM
    BioDrugs; 2018 Oct; 32(5):465-480. PubMed ID: 30132210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Catabolism of antibody drug conjugates and characterization methods.
    Shadid M; Bowlin S; Bolleddula J
    Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
    Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
    Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.
    Gorovits B; Krinos-Fiorotti C
    Cancer Immunol Immunother; 2013 Feb; 62(2):217-23. PubMed ID: 23223907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
    Singh D; Dheer D; Samykutty A; Shankar R
    J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates.
    Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR
    Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody drug conjugates: Design implications for clinicians.
    Pang S; Duong A; Siu C; Indorf A
    J Oncol Pharm Pract; 2024 Jul; 30(5):907-918. PubMed ID: 38651308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
    Kamath AV; Iyer S
    Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical development of antibody-drug conjugates - lessons from leukaemia.
    Jabbour E; Paul S; Kantarjian H
    Nat Rev Clin Oncol; 2021 Jul; 18(7):418-433. PubMed ID: 33758376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals.
    Datta-Mannan A; Choi H; Jin Z; Liu L; Lu J; Stokell DJ; Murphy AT; Dunn KW; Martinez MM; Feng Y
    PLoS One; 2024; 19(4):e0293703. PubMed ID: 38630694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.